Immunosuppressive therapy: Difference between revisions
From IDWiki
(→) |
(→: linkified, added more about ibrutinib) |
||
| Line 20: | Line 20: | ||
! Specific Risks |
! Specific Risks |
||
|- |
|- |
||
| Eculizumab |
| [[Eculizumab]] |
||
| C5 complement |
| C5 complement |
||
| Meningococcus (very high risk), needs MCV4 + MenB + pen prophylaxis |
| Meningococcus (very high risk), needs MCV4 + MenB + pen prophylaxis |
||
|- |
|- |
||
| Rituximab |
| [[Rituximab]] |
||
| CD20, on B cells |
| CD20, on B cells |
||
| Long-term B cell depletion |
| Long-term B cell depletion |
||
|- |
|- |
||
| Natalizumab |
| [[Natalizumab]] |
||
| α4-integrin, on all leukocytes except neutrophils |
| α4-integrin, on all leukocytes except neutrophils |
||
| JC virus |
| JC virus |
||
|- |
|- |
||
| Ibrutinib |
| [[Ibrutinib]] |
||
| Bruton's tyrosine kinase (BTK), on B cells |
| Bruton's tyrosine kinase (BTK), on B cells |
||
| Invasive aspergillosis and other fungal infections |
|||
| |
|||
|} |
|} |
||
Revision as of 00:50, 15 October 2019
Screening
Before starting immunosuppressive therapy, consider the following investigations:
- Tuberculin skin test
- Strongyloides serology, if from endemic country
- Hep B and C serology
- Cytomegalovirus serology
- HIV serology
Management
- Latent TB infection: start treatment at least 4 weeks prior to starting the biologic
Specific Medications
| Medications | Target | Specific Risks |
|---|---|---|
| Eculizumab | C5 complement | Meningococcus (very high risk), needs MCV4 + MenB + pen prophylaxis |
| Rituximab | CD20, on B cells | Long-term B cell depletion |
| Natalizumab | α4-integrin, on all leukocytes except neutrophils | JC virus |
| Ibrutinib | Bruton's tyrosine kinase (BTK), on B cells | Invasive aspergillosis and other fungal infections |
